Vamorolone (Agamree) in Duchenne Muscular Dystrophy: A Steroid That Does Not Steal Growth
Ukraine, Dnepr, st. 25 Sicheslavskaya Brigade (Rybinskaya St.), 119 ‑ 120
Ukraine, Dnepr, st. 25 Sicheslavskaya Brigade (Rybinskaya St.), 119 ‑ 120

Vamorolone (Agamree) in Duchenne Muscular Dystrophy: A Steroid That Does Not Steal Growth

Vamorolone (Agamree) in Duchenne muscular dystrophy: the anti-inflammatory action of steroids without the growth delay — in VISION-DMD growth percentile +3.86 versus −1.88 on prednisone. How it works, how it is taken and who should see a doctor first.

Vamorolone (Agamree) in Duchenne Muscular Dystrophy: A Steroid That Does Not Steal Growth
Vamorolone (Agamree) is a steroid for Duchenne muscular dystrophy that keeps the anti-inflammatory action of steroids while touching growth and bone less: it binds the same receptor as prednisone but does not switch on all of its programmes. In the trial, children on prednisone lost growth percentile while those on vamorolone gained it, with comparable effects on motor function.

Key points

Vamorolone (brand name Agamree) is a dissociative steroid: approved by the FDA in October 2023 for Duchenne muscular dystrophy from age 2, it is given to children and adults in place of a conventional glucocorticoid.

WhereHow it helpsWhat human studies showed
Muscle and movementkeeps the anti-inflammatory actionVISION-DMD, 121 boys, 24 weeks: on 6 mg/kg/day, time-to-stand velocity 0.05 m/s versus −0.01 m/s on placebo (p=0.002) [1]
Growthweaker effect on growth than prednisonegrowth percentile fell by 1.88 on prednisone and rose by 3.86 on vamorolone 6 mg/kg (p=0.02) [1]
Bonedid not suppress bone turnover in the trialbone turnover markers declined on prednisone, not on vamorolone [1]
Switching from prednisonegrowth improves, bone measures return toward normalgrowth improved and bone measures returned toward normal [2]
Fluid retentionattenuated: blocks the mineralocorticoid receptor—

How it helps

What Breaks in This Disease

The muscle fibre has a shock-absorbing protein: dystrophin. It holds the fibre's membrane intact during contraction. In Duchenne muscular dystrophy the dystrophin gene is damaged and the protein is not made.

The result: every contraction damages the muscle a little. Fibres die and are replaced by fat and connective tissue. First the child loses the ability to run, then to walk; later the respiratory muscles and the heart are affected. Almost only boys are affected.

Why Steroids Cannot Be Avoided

Glucocorticoids do not repair the gene or restore dystrophin. But they damp the inflammation that accompanies fibre breakdown, and thereby slow the destruction. They are proven to extend the ability to walk by years.

So they are not abandoned, though the cost is high — and highest for a growing child:

▸ growth delay;
▸ fragile bones, vertebral fractures;
▸ weight gain;
▸ cataract;
▸ changes in behaviour and mood;
▸ adrenal suppression.

The Same Receptor, a Different Set of Programmes

An ordinary glucocorticoid entering the cell binds its receptor — and switches on a whole set of programmes at once. Some damp inflammation, others slow bone growth, others alter metabolism. It all arrives as one package.

Vamorolone binds the same receptor but does not activate the entire set: the anti-inflammatory part is kept, while some of the pathways leading to growth delay and bone loss are engaged less. It additionally blocks the mineralocorticoid receptor, associated with fluid retention.

Hence the name of the class — dissociative steroids: they separate what is inseparable in ordinary hormones.

What the Trial Showed

▸ VISION-DMD (JAMA Neurology, 2022) — 121 boys, mean age 5.4 years, 24 weeks [1].

The primary measure was time-to-stand velocity, an ability that deteriorates earlier than many others in this disease. On 6 mg/kg per day it was 0.05 m/s versus −0.01 m/s on placebo (95% CI 0.02–0.10; p=0.002). The first four secondary endpoints were also met, the six-minute walk test among them.

The most important part is the comparison with prednisone (figures in “Key points”): the difference is not one of degree but of direction — one group fell further behind their peers, the other did not.

▸ 48-week extension (Neurology, 2024) — motor improvement was maintained. In children switched from prednisone to vamorolone, growth improved and disturbed bone measures returned toward normal [2].

How to take it

Vamorolone is taken in place of a conventional glucocorticoid, as planned by a physician; in the trial the effect was shown on 6 mg/kg per day [1].

Who should see a doctor first

Adrenal glands. Adrenal suppression developed in all three groups of the trial, vamorolone included [3]. The practical consequence is the same as for any steroid: the drug must not be stopped abruptly, and during illness, injury or surgery the dose has to be adjusted. Families are told this before treatment starts, not after the fact.

Who It Is Not For

▸ As an addition to a conventional glucocorticoid: it is a replacement, not an add-on — two steroids are not prescribed together.
▸ During active infection and in other situations where any glucocorticoid is contraindicated.
▸ As grounds for stopping the previous hormone abruptly: the switch is planned by a physician, accounting for suppressed adrenal function.
▸ As a substitute for the rest of care: physiotherapy, cardiac and respiratory monitoring and orthopaedic follow-up all remain.

Bottom Line

▸ The same receptor, a different set of programmes: anti-inflammatory action preserved, impact on growth and bone attenuated.
▸ The motor effect is proven against placebo: time-to-stand velocity 0.05 versus −0.01 m/s.
▸ Switching from prednisone returned growth and bone measures toward normal.

Treatment can be discussed at a consultation; the drug can be ordered here.

References

1. Guglieri M, et al. Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial. JAMA Neurol. 2022;79(10):1005–1014. PMID 36036925

2. Dang UJ, et al. Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy: A Randomized Controlled Trial. Neurology. 2024;102(5):e208112. PMID 38335499

3. Ahmet A, et al. Adrenal Suppression From Vamorolone and Prednisone in Duchenne Muscular Dystrophy. J Clin Endocrinol Metab. 2025;110(2):334–344. PMID 39097643

4. AGAMREE (vamorolone) — US Prescribing Information, Catalyst Pharmaceuticals.

Source: Vamorolone (Agamree) in Duchenne Muscular Dystrophy: A Steroid That Does Not Steal Growth — universum.earth. Dr. Pereligyn.

Come back
Request a call back